# Gut Microbiome Diversity and GVHD Prophylaxis in Hematopoietic Cell Transplantation A phase 3 clinical trial examines how different prophylaxis regimens affect patient gut microbiomes. - **Source:** [Nature Medicine](https://www.nature.com/nm) - **Published:** 2026-11-12 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/388b3dfd-8694-4e0c-9a88-167197c9cfe6 ## Study Context and Objectives Allogeneic hematopoietic cell transplantation is a curative procedure for hematological disorders, yet graft-versus-host disease remains a major complication. The BMT CTN 1801 study, a companion to the 1703 trial, investigated the relationship between gut microbiome diversity and clinical outcomes. Researchers analyzed 2,575 stool samples from 304 participants undergoing reduced-intensity conditioning regimens. ## Prophylaxis Regimen Comparison The trial compared two prophylaxis regimens: standard tacrolimus with methotrexate versus the experimental post-transplant cyclophosphamide approach. Results indicated that microbiome diversity and absolute microbial load were lower in the cyclophosphamide group during the early post-transplant period, specifically between days 14 and 28, regardless of any concurrent antibiotic exposure. ## Primary Endpoint Analysis The primary objective was to determine if microbiome diversity at neutrophil engraftment predicted non-relapse mortality after one year. Statistical analysis revealed no significant association between engraftment diversity and non-relapse mortality, with a P-value of 0.314. This finding contrasts with earlier observational studies that suggested a stronger link in diverse cohorts. ## Baseline Diversity Significance While engraftment diversity showed no predictive power, baseline microbiome diversity proved clinically relevant. Patients in the lowest diversity tertile experienced significantly shorter overall survival compared to those with higher diversity. This association remained statistically significant as a linear predictor, suggesting that pre-transplant gut health influences long-term patient recovery and survival. ## Microbial Domination Events Microbial domination, defined as a single species exceeding 30% relative abundance, was monitored throughout the study. Interestingly, the frequency of these events did not differ significantly between the two prophylaxis arms. These events reflected a mix of pathogen blooms and less severe disruptions, occurring independently of the specific treatment regimen administered. ## Metabolic Pathway Alterations The study identified specific metabolic differences between the treatment groups following transplantation. Clostridium scindens and secondary bile-acid metabolism pathways were notably less prevalent in the cyclophosphamide arm compared to the tacrolimus/methotrexate group. These pathways are often linked to immunomodulatory activity, potentially influencing how the host immune system responds to donor cells. ## Antibiotic Exposure Impact Researchers evaluated the impact of antimicrobial exposure during the first 30 days post-transplant on clinical outcomes. Higher exposure to antibacterials was associated with an increased risk of developing grade II–IV acute graft-versus-host disease. This finding aligns with previous clinical reports highlighting the detrimental effects of broad-spectrum antibiotics on transplant recovery. ## Clinical Trial Methodology The study utilized metagenomic sequencing to profile species-level taxonomy across 304 participants. Engraftment was defined as the first of three days with an absolute neutrophil count of at least 500 cells per microliter. By standardizing these definitions across a multicenter framework, the researchers ensured consistent data collection for all enrolled patients. ## Addressing Non-Neutropenic Participants A subset of 34 participants did not experience a decline in neutrophil count below 500 cells per microliter. To maintain analytical integrity, researchers performed sensitivity analyses using day-14 stool samples for these individuals. These models confirmed the primary findings, demonstrating a lack of consistent association between engraftment diversity and clinical outcomes. ## Safety and Adverse Events Safety data were tracked throughout the trial, with cardiac and gastrointestinal disorders identified as the most common Grade 3–5 adverse events. Over the course of the study, 71 deaths were recorded among the 324 co-enrolled participants. These outcomes were consistent with the broader safety profile reported in the companion 1703 publication. ## Complex Immune Interactions The study suggests that prophylaxis regimens exert independent effects on both the microbiome and immune compartments. Because these treatments can impact the interaction between microbes and host immunity, simple interventions may not suffice. Future research must carefully disentangle these complex biological effects within the specific context of each unique treatment regimen. ## Future Research Directions Understanding how to leverage the microbiome to improve transplant outcomes remains a critical goal. Future studies should focus on whether microbiome-targeted interventions can mitigate adverse effects in the era of modern prophylaxis. Disentangling the independent roles of immune modulation and microbial health is essential for developing effective, personalized patient care strategies. ## Sources covering this story - https://www.nature.com/articles/s41591-026-04712-z — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._